Eli Lilly and Co (NYSE:LLY)
$ 775.3453 -2.4247 (-0.31%) Market Cap: 736.89 Bil Enterprise Value: 763.34 Bil PE Ratio: 116.14 PB Ratio: 57.52 GF Score: 81/100

Eli Lilly and Co to Discuss Diabetes Portfolio Update at ADA Call Transcript

Jul 01, 2021 / 02:00PM GMT
Release Date Price: $231.13 (+0.70%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Diabetes Update at ADA. (Operator Instructions) As a reminder, today's call is being recorded.

I will now turn the call over to your host, Sara Smith. Please go ahead.

Sara Smith
Eli Lilly and Company - Director of IR

Good morning. Thank you for joining us for Eli Lilly and Company's Diabetes Business Update. I'm Sara Smith, Director of Investor Relations. Joining me on today's call are Mike Mason, President of Lilly Diabetes; Dr. Jeff Emmick, Vice President of Diabetes Product Development; Dr. Ruth Gimeno, Vice President of Diabetes and Metabolic Research; and Jamie Croaning, Global Development Leader for tirzepatide.

During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3. Additional information concerning factors that could cause actual results to differ materially is contained in our latest

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot